For the quarter ending 2026-03-31, MBOT had -$56K decrease in cash & cash equivalents over the period. -$5,161K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -3,671 | -3,464 | -3,577 | -6,101 |
| Depreciation of property and equipment | 12 | 10 | 10 | 27 |
| Interest income and unrealized gains from marketable securities | -60 | - | 163 | 119 |
| Share-based compensation | 222 | 236 | 328 | 493 |
| Accounts receivable | 105 | - | - | - |
| Inventory | 1,673 | 584 | - | - |
| Prepaid expenses and other assets | - | 7 | 336 | -161 |
| Insurance recovery related to legal settlement and legal expenses received in cash | - | - | - | 0 |
| Accounts payable and accrued liabilities | - | 495 | - | - |
| Legal settlement paid in cash | - | - | - | 0 |
| Change in long-term deposit | - | 737 | - | - |
| Other payables and accrued liabilities | 395 | - | -103 | 92 |
| Proceeds from maturities of marketable securities | - | - | - | 0 |
| Net cash flows used in operating activities | -5,053 | -3,758 | -3,841 | -5,447 |
| Purchases of property and equipment | 108 | 25 | 13 | 22 |
| Purchase of marketable securities | - | 3,008 | 48,000 | 31,918 |
| Purchases of marketable securities | 441 | - | - | - |
| Proceeds from sales of a marketable securities | 6,500 | 1,500 | 3,301 | 5,801 |
| Increase in long-term deposit | 148 | - | - | - |
| Increase in restricted deposit | 806 | - | - | - |
| Net cash flows provided by (used in) investing activities | 4,997 | -1,533 | -44,712 | -26,139 |
| Issuance of common stock and warrants, net | - | - | 83,733 | - |
| Issuance of common stock and warrants, net of issuance costs | - | 53,681 | - | 32,558 |
| Exercise of options | - | 0 | 1 | - |
| Net cash flows provided by financing activities | - | 2,506 | 51,176 | 32,558 |
| (decrease) increase in cash, cash equivalents and restricted cash | -56 | -2,785 | 2,623 | 972 |
| Cash, cash equivalents and restricted cash at beginning of period | 3,973 | 6,758 | 3,163 | - |
| Cash, cash equivalents and restricted cash at end of period | 3,917 | 3,973 | 6,758 | - |
Microbot Medical Inc. (MBOT)
Microbot Medical Inc. (MBOT)